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Abstract
c-Src, a well-known proto-oncogene, mediates tumor progression 
properties including proliferation, angiogenesis, adhesion, and migration. It is 
well-characterized that the stability of active c-Src is regulated by
ubiquitination while other post-translational modifications of c-Src have been
unknown. Here, I found that the stability of c-Src is regulated by neddylation.
Furthermore, c-Cbl turned out as an E3 ligase for conjugation of NEDD8 to c-
Src. Moreover, the inhibition of c-Src neddylation markedly blocked its 
ubiquitination. To my surprise, the blockade of neddylation by NAE inhibitor 
MLN4924 or si-NEDD8 promoted cancer cell migration through the elevated 
stability of c-Src. Such consequences by inhibition of neddylation were 
abolished either by the treatment of Src-family kinase inhibitor PP2 or c-Src-
targeting siRNA. Also the blockade of neddylation activated PI3K/Akt/mTOR
pathway in a c-Src-dependent manner. Inhibitors of PI3K/Akt/mTOR pathway 
also could abolish cancer cell migration induced by MLN4924. Taken 
together, c-Src was identified as a novel substrate for neddylation that 
facilitates ubiquitination-dependent degradation, which blocks the migration
of cancer cells via PI3K/Akt/mTOR pathway. My study provided a new 
insight about the effect of c-Src modification in tumor progression.
ii














Abstract in Korean ...........................................................................55
iv
LIST OF FIGURES
Figure 1. The protein levels of c-Src and phospho-Y416 Src are elevated with 
the inhibition of neddylation ..................................................................... 19
Figure 2. Half-life of c-Src is increased with the blockade of neddylation.. 21
Figure 3. NEDD8-conjugation of c-Src. .................................................... 23
Figure 4. Neddylation of c-Src is regulated by c-Cbl ................................. 25
Figure 5. Activation of c-Src facilitates its neddylation.............................. 27
Figure 6. Neddylated c-Src is further ubiquitinated and degraded .............. 39
Figure 7. Blockade of neddylation promotes cancer cell migration ............ 31
Figure 8. Cell migration is promoted with blockade of NEDD8 process..... 33
Figure 9. Neddylation-mediated cancer cell migration is regulated via c-Src-
dependent way .......................................................................................... 35




EGFR: Epidermal growth factor receptor
PI3K: Phosphoinositide 3-kinase
ERK: Extracellular signal-regulated kinase
MMP: Matrix metallopeptidase
FAK: Focal adhesion kinase
NEDD8: Neural precursor cell-expressed developmentally down-regulated 8
APPBP1: Amyloid beta precursor protein binding protein 1
SENP8: Sentrin-specific protease 8
Cbl : Casitas B-lineage lymphoma
mTOR : Mechanistic target of Rapamacin
1
INTRODUCTION
c-Src, a well known proto-oncogene, is activated or overexpressed in about 
50% of tumors from colon, liver, lung, breast and the pancreas (Dehm and 
Bonham, 2004). As an upstream kinase of many signal pathways, c-Src 
mediates tumor progression properties including proliferation, angiogenesis, 
adhesion, and migration (Yeatman, 2004). Among these, c-Src can promote 
cell migration by activating diverse downstream molecules. EGFR, one of the 
major receptor tyrosine kinases (RTKs), is known for both enhancing the
oncogenic properties with c-Src overexpression and causing aggressive 
migration in tumor cells (Maa et al., 1995; Bao et al., 2003). It was reported 
that the downstream kinase pathways of c-Src including PI3K/Akt and 
MEK/ERK participate in c-Src mediated cell migration (Guarino, 2010). It 
was presented that the RANKL-induced cell migration in breast cancer was 
mediated by c-Src through activating ERK and Akt (Zhang et al., 2012). IL-
1b-induced MMP-9 expression and cell migration have been shown to be 
mediated via transactivation of EGFR/PDGFR/PI3K/Akt/NF-kB pathway by 
c-Src (Cheng et al., 2010). Also c-Src activates ERK/Sp1/MMP2 pathway, 
which elevates cell migration capacity (Kuo et al., 2006; Wu et al., 2016). 
Although c-Src plays an important role in cancer cell migration and 
invasion, the regulations of its function and stability are not well-known.
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Among the few, one of the known processes that regulates c-Src stability is 
ubiquitination. The active c-Src protein levels can be regulated by the 
ubiquitination-dependent degradation pathway. It was identified that the 
activation of c-Src increased its poly-ubiquitination (Harris et al., 1999; 
Hakak and Martin, 1999). In the process of ubiquitination for various tyrosine 
kinases, Cbl-family proteins are known to act as E3 ligases (Mohapatra et al., 
2013). Cbl-family regulates the stability of c-Src as well. Cbl-c binds to
phosphorylated c-Src at Y416 and induces ubiquitination of c-Src (Kim et al., 
2004). Another protein of Cbl-family, c-Cbl, is phosphorylated by active c-Src, 
faciliating the ubiquitination of c-Src (Yokouchi et al., 2001). Consistent with 
these reports, c-Cbl also mediates cell migration through regulation of diverse 
molecules. For example, aPix-mediated cell migration and invasion were
negatively regulated by c-Cbl (Seong et al., 2014). Furthermore, c-Cbl 
inhibited FAK/Src/GRB2 nexus, limiting cell migration in melanoma cells
(Nihal and Wood, 2016). On the other hand, in glioma invasion, c-Cbl 
promoted upregulation of MMP2 (Lee and Tsygankov, 2010).
Apart from its ubiquitin-E3 ligase function, c-Cbl has another ligase 
function to conjugate small ubiquitin-like molecule, NEDD8. Protein 
neddylation is a process that NEDD8 covalently conjugates to other proteins
(Kumar et al., 1993). Neddylation process is carried out through three steps 
similar to ubiquitination. First, E1 enzyme, namely NAE complex which is 
3
composed of APPBP1 and UBA3, activates NEDD8. Followed by activation, 
conjugation of NEDD8 is conducted by unique neddylation E2 enzyme, 
UBC12. The last step determining substrate specificity is proceeded by 
various NEDD8-E3 ligases (Gong and Yeh, 1999). Neddylation has diverse 
effects on its substrate proteins. First, it can activate ubiquitin transfer 
function of E3 ligases. Cullin, a component of Cullin-RING ubiquitin ligases
(CRLs), is conjugated with NEDD8 and activates the ubiquitin transfer 
activity (Bennett et al., 2010). Likewise, an ubiquitin-E3 ligase function of 
SMURF1, is facilitated by its neddylation (Xie et al., 2014). Secondly, 
neddylation regulates transcriptional activity of some transcription factors. 
p53 is identified to be neddylated by MDM2 NEDD8-E3 ligase, which 
inhibits the transcriptional activity (Xirodimas et al., 2004). Another 
transcription factor, E2F1, which controls cell proliferation and cell death, is 
also neddylated and results in interruption of the target specificity (Aoki et al., 
2013). Neddylation is also well-known to alter the stability of its substrates. 
MDM2 conjugated NEDD8 to itself, thus bringing out its stabilization 
(Xirodimas et al., 2004; Watson et al., 2010). HIF-1a is also a target of 
neddylation. It promotes stabilization of this transcription factor (Ryu et al., 
2011). When it comes to the function of c-Cbl as a NEDD8-E3 ligase, it 
causes the opposite effects to the known two substrates. c-Cbl conjugates
NEDD8 to TGF-b type II receptor and improves protein stability by inhibiting 
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ubiquitination (Zuo et al., 2013). On the other hand, c-Cbl mediated 
neddylation of EGFR facilitates further ubiquitination and degradation (Oved
et al., 2006).
Beyond the regulation of protein functions, neddylation also causes 
considerable changes to the cellular physiology. Given that a NEDD8 
pathway affects many CRL substrates, it is not surprising that the neddylation 
process is involved in various types of cancers (Duncan et al., 2012). In fact, 
neddylation substrates found to be relevant in many kinds of cancers. For 
instance, MDM2 is included in typical cancers (Xirodimas et al., 2004). VHL, 
whose neddylation prevents interaction between CUL2 and fibronectin, is
implicated in renal cancer (Ohh et al., 2003; Stickle et al., 2004). 
Gastrointestinal cancer involves disruption of IKKg neddylation with increase 
of NF-kB signaling (Noguchi et al., 2011). Above these, many other 
neddylation substrates such as SCCRO, HuR, and CUL-1 showed relevancy 
with various cancers (Sakaria et al., 2006; Salon et al., 2007; Embade et al., 
2012). Because of its interrelationship with tumor progression, neddylation 
has been receiving great attention as a therapeutic target for cancer treatments 
(Soucy et al., 2010). In particular, the inhibition of NEDD8-pathway was 
revealed to have a therapeutic potential (Abidi et al., 2015). One of the 
pharmacological methods to inhibit neddylation process is to treat MLN4924. 
MLN4924 is a selective inhibitor of neddylation-activating enzyme (NAE). 
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As MLN4924 has a similar structure with adenosine 5’-monophosphate
(AMP), it bounds in the nucleotide-binding site of NAE (Bohnsack and Haas, 
2003; Walden et al., 2003). Many studies reported about the fine effects of 
MLN4924 in cancers. It exhibited cytotoxic effects against variety of human-
derived cancer cell lines and anti-tumor activity in xenografted mice (Soucy et 
al., 2009). Also MLN4924 was found to induce autophagy in liver cancer cells, 
promoting its apoptosis (Luo et al., 2012). In gastric cancer, this NAE 
inhibitor markedly suppresses cell migration via activating E-cadherin and 
reducing MMP-9 (Lan et al., 2016). Moreover, MLN4924 shows great effects
for decreasing tumor progression in different types of cancers (Millhollen et 
al., 2010; Nawrocki et al., 2013; Wang et al., 2014). However, it was recently 
claimed that the treatment of MLN4924 facilitated formation of tumor-sphere 
via EGFR-dependent pathway in vitro and in vivo systems (Zhou et al., 2016).
Given that MLN4924 induces phosphorylation of Y845 of EGFR, a well-
known residue as the target of c-Src mediated phosphorylation (Sato, 2013; 
Zhou et al., 2016), I assumed that the phosphorylation of c-Src may also be
influenced by the neddylation process. For now, there is no direct evidence 
that c-Src is post-translationally modified by neddylation. In this study, I
identified that the stability of c-Src is regulated by neddylation. Furthermore, 
c-Cbl turned out as an E3 ligase for conjugation of NEDD8 to c-Src. The 
inhibition of c-Src neddylation markedly blocked its ubiquitination. Moreover, 
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blockades of neddylation by NAE inhibitor MLN4924 or si-NEDD8 
facilitated cancer cell migration through the elevated stability of c-Src. Such 
consequences by the inhibition of neddylation were abolished either by the 
treatment of Src-family kinase inhibitor PP2 or c-Src-targeting siRNA.
Furthermore, the activated form of c-Src downstream kinases; phospho-
Akt/mTOR were increased by the blockade of neddylation and the inhibition 
of these kinases by inhibitors interrupted MLN4924-induced migratory effect 
of cancer cells. Taken together, c-Src was identified as a novel substrate for 
neddylation that facilitates ubiquitination-dependent stability, which mediates




Antibodies against APPBP1 (Novus Biologicals, Littleton, CO), FLAG-tag 
(Sigma-Aldrich, St.Louis, MO), HA-tag (Genetex, Irvine, CA), c-Src,
phospho-Y416 Src, Myc-tag, NEDD8, Akt, phospho-S473 Akt, ERK, 
phospho-p44/42 (Erk1/2), phospho-S2448 mTOR (Cell Signaling Technology, 
Danvers, MA), β-tubulin, Cbl, and c-myc (Santa Cruz Biotechnology, Dallas, 
TX) were obtained from the indicated companies. Cycloheximide, MG132 
(Sigma-Aldrich), PP2 (Calbiochem, La Jolla, CA), LY294002, MK-2206, and 
Rapamycin (Selleck Chemicals, Houston, TX) were purchased from the 
indicated companies. MLN4924 was synthesized as previously described (Lee 
et al., 2011).
Cell Culture
HEK293 (a human embryonic kidney cell), H1299 (a human non-small 
cell lung carcinoma cell), HCT116 (a human colon carcinoma cell), U87MG 
(a human glioblastoma), and PC3 (a human prostate cancer cell) cell lines 
were obtained from the American Type Culture Collection (Manassas, VA). 
HEK293, H1299 and HCT116 cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM). U87MG and PC3 cells were maintained in 
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MEM/EBSS and RPMI1640 medium, respectively. All medium were 
supplemented with 10% heat-inactivated fetal bovine serum, penicillin and 
streptomycin. All cells were incubated in 5% CO2 at 37 
oC.
Plasmids and Short interfering RNAs (siRNAs)
His6-tagged NEDD8, mutant NEDD8 (NEDD8-ΔGG; which is unable to
conjugate with target proteins), HA-Ubiquitin, and Myc-SENP8 were 
constructed as previously described (Park et al., 2016). PCR-amplified 
cDNAs of human c-Src were inserted into Myc-tagged pcDNA. FLAG-tagged 
constitutive active form (Y527F) and dominant negative form (K295R, 
Y527F) of Src were provided by Professor Yang Young (Park et al., 2015).
FLAG-tagged c-cbl was given by Professor Chin-Ha Chung (Seong et al., 
2014). The siRNAs used in experiments were synthesized by M.biotech 
(Hanam-si, Gyeongi-do). The targeting sequences of APPBP1 (NM_003905) 
were 5’-GGACAAUCCAGAUAAUGAAAUAGTG-3’ (# 1) and 5’-GGAUC-
UACGACUAGAUAAGCCAUTT-3’ (# 2), corresponding to exon 17 and 8, 
respectively. The targeting sequence of c-Cbl (NM_005188) was 5’-
GAAGUUACCCUAAUAAUCCAAAGATG-3’, corresponding to exon 16. 
The sequences of siRNAs targeting NEDD8 (NM_006156) were 5’-
AGCGGUAGGAGCAGCAAUUUAUCCG-3’ (# 1) and 5’-GAAGAUGCU-
AAUUAAAGUGAAGACG-3’ (# 2), corresponding to exon 1 and 2, 
9
respectively. The targeting sequence of c-Src (NM_198291) was 5’-
AGAGAAACCUGGUGUGCAAAGUGGCC-3’, corresponding to exon 10. 
The control siRNA sequence was 5’-UUGAGCAAUUCACGUUCAUTT-3’.
Western blotting and Immunoprecipitation
Total cells lysed with 2 X-SDS were separated on SDS/polyacrylamide 
gels and then transferred to Immobilon-P membranes (Millipore, Bedford, 
MA). Membranes were blocked with 5% skim milk or 1% skim milk and BSA 
in TTBS (tris-buffered saline containing 0.1% Tween 20) for 1 h, and 
incubated overnight with primary antibody diluted 1 : 500 to 1 : 3000 in the 
blocking solution or TTBS with 1% BSA. The membranes were further 
incubated with a horseradish peroxidase-conjugated secondary antibody for 1 
h and visualized using the ECL Plus kit (Thermo Fisher Scientific, Waltham, 
MA). 
To precipitate tagged proteins, transfected cells were lysed with buffer 
containing 5 mM EDTA, 50 mM Tris-Cl (pH 8.0), 100 mM NaCl, 0.1% NP-
40, and the protease inhibitor cocktail (Sigma-Aldrich). Cell lysates (1 mg 
proteins) were incubated with anti-HA or FLAG affinity beads (Sigma-
Aldrich) at 4 °C for 4 h. Proteins bound to the beads were eluted with a 2 X-
SDS or 3 X FLAG PEPTIDE (Sigma-Aldrich) and assessed to western 
blotting.
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Identification of His6-tagged NEDD8 Conjugates
Identification of NEDD8-conjugation was performed and modified based 
on the previous description (Jaffray and Hay., 2006). After transfection of 
plasmid DNA expressing His6-tagged NEDD8 or NEDD8-ΔGG, cells were 
divided into two dishes. One was lysed with 2 X-SDS sample buffer and 
analyzed by Western blotting to check the expression level of proteins (input 
samples). The other was mixed with denaturing buffer (6 M guanidine 
hydrochloride, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-Cl (pH 8.0), 10 mM 
imidazole and 10 mM β-mercaptoethanol). The lysates were incubated with 
Ni-NTA-agarose beads (Qiagen, Valencia, CA), prewashed with lysis buffer, 
and rotated for 4 h at room temperature. The beads were washed for 2 minutes
in each steps with the following solutions: lysis buffer (pH 8.0); washing 
buffer (pH 8.0) (Mixture of 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M 
Tris/HCl, pH 8.0, 20 mM imidazole and 10 mM β-mercaptoethanol); washing 
buffer (pH 6.3) plus 0.2% Triton X-100; and washing buffer (pH 6.3) plus 0.1% 
Triton X-100. Then, the beads were eluted with 2 X-SDS sample buffer and 
visualized by Western blotting.
Wound healing assay
H1299 cells transfected with appropriate vectors were cultured in 5% CO2
incubator at 37 oC until they became confluent. They were scratched with an 
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autoclaved 200μl pipette tip and washed twice with serum-free DMEM to 
remove the debris. In order to prevent proliferation, the cells were incubated 
in serum-free DMEM with or without the indicated reagents for 24 h, and 
photographed using a camera-equipped microscope.
Transwell migration assay
Transwell migration assay was performed using polycarbonate inserts 
(Corning, Newyork, NY) which has 8.0 mm size pores in 24-well cell culture 
plates as described by the manufacturer. The lower part was filled with 
DMEM containing 10% FBS and the upper part was filled with serum-free 
media. Cells (1.0 ~ 1.5 x 104) were added to upper chamber, and incubated for 
18 h at 37 oC. Non-invaded cells were removed from the membrane surface of 
the upper part using cotton swab. The migrated cells were fixed by MeOH and 
stained by solution with 1% Crystal Violet and 2% MeOH. The stained cells 
were photographed by microscope and the migration was analyzed by 
counting the number of stained cells in four randomly chosen fields per 
sample.
RNA isolation and RT-qPCR
Total RNA was isolated using Trizol reagent (Invitrogen, Calsbad, CA) 
according to the manufacturer’s protocol. cDNA synthesis and amplification 
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was performed with EasyScript cDNA Synthesis Kit (Applied Biological 
Materials Inc., Richmond, BC). cDNAs were amplified with EvaGreen qPCR 
master mix reagent (Applied Biological Materials) by StepOne Real-time 
PCR System (Applied Biosystems, Foster, CA). 18s ribosomal RNA was used 
as an internal control. The sequences of c-Src primer used in experiment were 




Neddylation Inhibits Stabilization and Activation of c-Src. 
Given that inhibition of neddylation by MLN4924 enhanced the
phosphorylation of EGFR at Y845 mediated by c-Src kinase (Zhou et al., 
2016), I examined whether c-Src is affected by the depletion of neddylation
via the treatment of MLN4924. To remove the effects of various growth 
factors affecting c-Src activation, I incubated cells in serum-free media for 24 
hours before MLN4924 treatment. Surprisingly, both the levels of c-Src and 
phospho-Y416 Src increased with the treatment of MLN4924 in H1299, 
HCT116, and PC3 cancer cell lines (Fig 1A). Consistently, the blockade of 
neddylation process through siRNAs targeting NEDD8 or APPBP1 enhanced
the levels of both c-Src and phospho-Y416 Src in H1299 cell line (Fig 1B). To 
understand the mechanism underlying the alteration of the c-Src protein levels, 
I evaluated the synthesis and degradation of c-Src proteins. First, the stability 
of c-Src was investigated using Cycloheximide (CHX) with or without 
MLN4924 treatment in H1299 cells. The total c-Src protein levels slowly 
decreased with the treatment of MLN4924, compared to the control (Fig 2A). 
The half-life of c-Src protein was 7.9 ± 3.9 hours in the control, but markedly 
increased to 14.5 ± 5.0 hours with MLN4924 treatment. In order to rule out 
the possibility of newly synthesized c-Src proteins, mRNA level of c-Src was 
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checked with or without MLN4924 (Fig 2B). There were no changes in 
mRNA level of c-Src. These results suggest that neddylation negatively 
regulates the stability and activity of c-Src.
NEDD8-conjugation of c-Src.
To examine whether c-Src is directly neddylated, His-N8 or His-N8ΔGG 
(conjugation-defective mutation of NEDD8) were co-transfected with Myc-
WT-Src into HEK293 cells and the neddylated proteins were isolated by Ni2+ 
affinity beads. Ectopically expressed c-Src was firstly identified to be 
conjugated with NEDD8, while failed with NEDD8ΔGG (Fig 3A). Besides, 
the NEDD8-conjugation of c-Src was effectively removed by co-transfection 
of Myc-SENP8, a de-neddylating enzyme (Fig 3B). These results indicate that 
c-Src is directly conjugated with NEDD8.
The role of c-Cbl as a NEDD8-E3 ligase for c-Src.
c-Cbl, a known ubiquitin and NEDD8-E3 ligase, is involved in diverse 
cellular pathways through regulation of tyrosine kinases (Mohapatra et al., 
2013). In particular, c-Cbl was identified to act as either ubiquitin or NEDD8-
E3 ligase for EGFR and ubiquitin-E3 ligase for c-Src (Yokouchi et al., 2001; 
Oved et al., 2006). Accordingly, to examine whether c-Cbl plays a role as 
NEDD8-E3 ligase for c-Src, the interaction between c-Src and c-Cbl was first 
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evaluated by immunoprecipitation. Ectopically expressed c-Src binds to c-Cbl 
as previously reported (Fig 4A; Szymkiewicz et al., 2004). Next, the extent of 
neddylation of c-Src was measured when c-Cbl was depleted by siRNA in 
H1299 cells. As expected, knockdown of c-Cbl decreased the level of c-Src 
neddylation (Fig 4B). In contrast, when c-Cbl was overexpressed in H1299 
cells, the neddylation of c-Src was increased (Fig 4C). Therefore, these results 
suggest that c-Cbl plays a role as a NEDD8-E3 ligase for c-Src.
c-Src activation facilitates its neddylation.
As the phosphorylation of c-Cbl at Y371 residue mediated by c-Src
ubiquitinates itself as well as c-Src (Yokouchi et al., 2001), I examined
whether the phosphorylation of c-Src could affect the neddylation of itself.
The extent of neddylation of c-Src was measured using Ni2+ column in 
U87MG and H1299 cells expressing Myc-WT-Src and His-NEDD8 with or 
without PP2, a selective Src inhibitor. Neddylation of c-Src decreased in the
presence of PP2 (Fig 5A). Consistent with this result, constitutive active form 
of c-Src (FLAG-CA-Src) was more neddylated than the dominant negative 
form (FLAG-DN-Src) (Fig 5B). These results indicate that the neddylation of 
c-Src is facilitated with its activation.
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c-Src neddylation regulates its ubiquitination.
Given that EGFR conjugated with NEDD8 is facilitated to be ubiquitinated 
and degraded by the 26S proteasome system (Oved et al., 2006), I assumed 
that ubiquitination of activated-Src might also be regulated by its neddylation. 
To examine this, I assessed the level of ubiquitinated c-Src by 
immunoprecipitation with or without MLN4924 treatment in H1299 cells. As 
in Figure 6A, inhibition of neddylation by MLN4924 caused a decrease of c-
Src ubiquitination. Also the de-neddylation through SENP8 effectively 
reduced the ubiquitination of c-Src (Fig 6B). These results suggest that the 
neddylation of c-Src facilitates its ubiquitination process.
Blockade of neddylation promotes cell motility in a c-Src-dependent 
pathway.
I have shown that c-Cbl facilitates conjugation of neddylation to c-Src, 
further inducing ubiquitination of the c-Src. c-Cbl is known to regulate the 
cell migration negatively, while c-Src promotes cell motility in cancers 
(Guarino, 2004; Seong et al., 2014; Nihal and Wood, 2016). Therefore, I 
examined whether neddylation can control cancer cell migration through c-
Src-dependent pathway. First, metastasis in H1299 lung cancer cell line was 
evaluated. In a monolayer wound healing assay, the cells treated with 
MLN4924 has shown more migration than the untreated cells (Fig 7A). 
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Furthermore, the migration in the cells of which neddylation was blocked by 
the siRNA targeting NEDD8 increased than the control (Fig 7B). The 
migratory effect by inhibition of neddylation was further assessed by 
transwell migration assay. The MLN4924 treated H1299 cells showed greater 
migration capacity than the control (Fig 8A). Also the migration in the cells 
with knocked down expression of NEDD8 increased compared to the control 
(Fig 8B). Next, to examine whether the enhanced cell motility by blocking of
neddylation is dependent on c-Src, the cell motility was evaluated in the cells 
expressing siRNA targeting c-Src with MLN4924 treatment. The rate of 
migration increased with MLN4924 in the cells expressing control siRNA, but 
decreased in cells expressing si-Src (Fig. 9A). However, the inhibition of c-
Src could not block the cell motility completely. This could be reason that c-
Src might not be sufficiently depleted with tested siRNA (Fig. 9A, lower 
panel) or other various pathways in cell motility might be influenced by 
neddylation inhibition. Furthermore, the elevated cell migration by MLN4924 
was markedly reduced with the treatment of c-Src inhibitor, PP2 (Fig. 9B). 
Therefore, cell motility is increased with the blockade of neddylation via c-
Src pathway.
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Blockade of neddylation facilitates PI3K/Akt/mTOR signaling in a c-Src-
dependent way.
Next, I investigated which downstream signaling is affected by the 
neddylation of c-Src. Previous reports have shown that c-Src mediates 
PI3K/Akt and MEK/ERK pathways, promoting cell migration (Kuo et al., 
2006; Cheng et al., 2010; Zhang et al., 2012; Wu et al., 2016). Therefore, 
protein levels of Akt, ERK, and their kinase-active forms were evaluated with 
the treatment of MLN4924 and PP2 in H1299 cells. The level of kinase-active 
form of Akt (phospho-S473 Akt) dramatically increased with MLN4924 
treatment while the levels of Akt, ERK, and phospho-ERK barely changed
(Fig 10A). Furthermore, the downstream kinase of Akt, mTOR, was also 
activated in presence of MLN4924. Elevated levels of phospho-S473 Akt and 
phospho-S2448 mTOR by MLN4924 were reduced with the treatment of PP2.
Next, to examine whether PI3K/Akt/mTOR pathway is involved in enhanced
cell motility through the inhibition of neddylation, the cell migration was 
evaluated in H1299 treated with MLN4924 and various inhibitors. In line with 
PP2, treatment of inhibitors of PI3K (LY294002), Akt (MK-2206), and mTOR
(Rapamycin) effectively interfered MLN4924-induced cell migration (Fig 
10B). These results suggest that the blockade of neddylation promotes cancer 





Figure 1. The protein levels of c-Src and phospho-Y416 Src are elevated 
with the inhibition of neddylation.  
(A) H1299, HCT116, PC3 cell lines were incubated in serum-free media for 
24 hours, following up with a treatment of MLN4924 for 24 hours in a dose 
dependent manner. The levels of c-Src and phospho-Y416 Src were analyzed 
by Western blotting. The band intensities of c-Src proteins (mean ± s.d, n=3) 
were calculated using ImageJ and plotted by the graph. (B) H1299 cells were 
transfected with siRNAs targeting NEDD8 or APPBP1. The proteins in total 


























Figure 2. Half-life of c-Src is increased with the blockade of neddylation.
(A) H1299 cells were pre-incubated with MLN4924 for 24 hours in serum-
free media and then incubated with cycloheximide for the indicated times. 
Cell lysates were subjected to Western blotting using anti-c-Src or anti-
phospho-Y416 Src antibody (upper panel). Band intensities (mean ± s.d , 
n=3) on the blots were analyzed using ImageJ and plotted (lower panel). (B) 
H1299 cells were incubated with MLN4924 for the indicated times. Total 






Figure 3. NEDD8-conjugation of c-Src.
(A) Myc-WT-Src plasmid was co-transfected with His-N8 or His-N8ΔGG 
into HEK293T cells. The protein lysates were purified with Ni2+ column and 
assessed by immunoblotting using specific antibodies. (B) HEK293T cells 
were transiently transfected with vectors encoding Myc-WT-Src, His-N8 and 
Myc-SENP8 (a de-neddylating enzyme). Proteins isolated using Ni2+ column 
were analyzed by Western blotting.
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Figure 4. Neddylation of c-Src is regulated by c-Cbl.
(A) H1299 cells expressing FLAG-c-Cbl and Myc-WT-Src were subjected to 
immunoprecipitation using Anti-FLAG affinity beads. Purified proteins were 
analyzed by Western blotting using indicated antibodies. (B) H1299 cell was 
co-transfected with indicated vectors with or without the siRNA targeting c-
Cbl. Proteins were filtered by Ni2+ column and visualized by immunoblotting. 
(C) FLAG-c-Cbl was co-transfected with Myc-WT-Src and His-N8 into 







Figure 5. Activation of c-Src facilitates its neddylation. 
(A) U87MG and H1299 cells were transfected with Myc-WT-Src and His-N8. 
48 hours after transfection, 10 mM of PP2 was added to the cells. Cell lysates 
were purified with Ni2+ column. (B) FLAG-tagged constitutive active form of 
Src or FLAG-tagged dominant negative form of Src was co-transfected with 
His-N8 into U87MG and H1299 cells. After purified with Ni2+ column, 





Figure 6. Neddylated c-Src is further ubiquitinated and degraded.
(A) H1299 cells transfected with indicated plasmids were incubated in serum-
free media and exposed to MLN4924 for 24 hours. Cell lysates were 
subjected to immunoprecipitation with HA-affinity beads and assessed to 
Western blotting. (B) Myc-SENP8 plasmid was co-transfected with Myc-WT-
Src and HA-Ubiquitin into H1299 cells. Cell lysates were analyzed by 
immunoprecipitation and immunoblotting.
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Figure 7. Blockade of neddylation promotes cancer cell migration. 
(A) H1299 cells were pre-incubated with serum-free media for 24 hours and 
subjected to wound healing assay with or without MLN4924 treatment. (B)
H1299 cells expressing si-Control or si-N8 were subjected to wound healing 
assay. Empty areas in A~B were quantified by using Image J software and
plotted. Cells were subjected to immunoblot analysis to verify the expression 
of c-Src and phospho-Y416 Src proteins. 
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Figure 8. Cell migration is promoted with blockade of NEDD8 process. 
(A) H1299 cells were pretreated with DMSO or MLN4924 for 24 hours and 
subjected to transwell migration assay with or without MLN4924. (B) H1299 
cells expressing si-Control or si-N8 were subjected to transwell migration
assay. The number of cells in four randomly chosen fields were counted and 
averaged. Data are the mean ± s.d (n = 3).
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Figure 9. Neddylation-mediated cancer cell migration is regulated via c-
Src-dependent way.
(A) H1299 cells transfected with si-Control or si-c-Src were treated with 
DMSO or 0.125 mM of MLN4924 and analyzed by wound healing assay. (B)
Cells pre-incubated with serum-free media for 24h were subjected to wound 
healing assay with 0.125 mM of MLN and 10 mM PP2 for indicated times. 
Empty areas in A~B were quantified by using Image J software and plotted.
Cells were subjected to immunoblot analysis to verify the expression of c-Src 



































Figure 10. Inhibition of neddylation promotes cell migration through the 
c-Src/PI3K/Akt/mTOR pathway.
(A) H1299 cells pre-incubated in serum-free media for 24h were treated with 
0.125 mM of MLN4924 and 10 mM of PP2. The cell lysates were subjected to 
immunoblotting. (B) Cells pre-incubated with serum-free media for 24h were 
subjected to wound healing assay with the treatment of various inhibitors 
(MLN4924: 0.125 mM; PP2: 10 mM; LY294002: 50 mM; MK-2206: 1 mM; 
Rapamycin: 0.1 mM). Empty areas were quantified by using Image J software 
and plotted. Cells were subjected to immunoblot analysis to verify the 
expression of the proteins.
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DISCUSSION
Although Src is the first confirmed oncogene in 1970s (Martin, 2001), its 
post-translational modifications have been scarcely identified so far. It is well 
defined that the activity of c-Src is controlled by its phosphorylation states. 
While phosphorylation of Y529 makes c-Src ‘inactive form’, phosphorylation 
of Y416 makes it ‘active form’. Also a phospho-Y416 Src is ubiquitinated and 
further degraded by 26S proteasome system (Guarino, 2004). Here, for the 
first time, I discovered that c-Src is regulated by another protein modification, 
neddylation. I ascertained that c-Src is directly neddylated through an E3 
ligase, c-Cbl (Fig. 3, 4). c-Cbl is well-known for its ubiquitin-E3 ligase 
activity targeting protein tyrosine kinases (PTKs) (Mohapatra et al., 2013).
Moreover, it was identified that c-Cbl can also act as a NEDD8-E3 ligase. Zuo 
et al reported that c-Cbl carries out neddylation of TGF-bIIR and it 
antagonizes conjugation of ubiquitins (Zuo et al., 2013). On the other hand, 
the other group found that c-Cbl mediated neddylation of EGFR promotes its 
ubiquitination (Oved et al., 2006). Interestingly, c-Cbl showed dual roles as 
neddylation and ubiquitin-E3 ligases of EGFR. Similar with this report, my 
results suggested that c-Cbl shows a NEDD8-E3 ligase activity for c-Src (Fig 
4). Furthermore, Blockade of neddylation efficiently prevented ubiquitination 
of c-Src. Given that c-Cbl conjugates ubiquitin to c-Src (Yokouchi et al., 
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2001), it seems that c-Cbl can play roles as both NEDD8 and ubiquitin-E3 
ligases of c-Src. 
The activity of c-Cbl is regulated by c-Src and EGFR. c-Src and EGFR 
phosphorylate Y371 residue of c-Cbl, facilitating its ubiquitin-E3 ligase 
function (Levkowitz et al., 1999; Yokouchi et al., 2003). EGFR-dependent 
phosphorylation of c-Cbl positively mediates its NEDD8-E3 ligase activity as 
well (Oved et al., 2006). According to my results, the activity of c-Src also 
seems to be important for its neddylation (Fig 5). It is likely that c-Src 
mediated phosphorylation of c-Cbl facilitates its NEDD-E3 function, which 
promotes c-Src neddylation. Thus, based on my results, I could formulate a 
stepwise model for c-Src modification. First, c-Src is activated through 
phosphorylation of Y416. Next, c-Src phosphorylates c-Cbl, promoting its 
NEDD8-E3 ligase activity. In turn, the activated c-Cbl conjugates NEDD8 to 
the c-Src. Then, ubiquitination of c-Src is further facilitated by c-Cbl. Finally, 
c-Src is destructed by 26S proteasome system. Consistent with my model, 
inhibition of neddylation effectively increased the stability and activity of c-
Src (Fig 1, 2). However, although neddylation of c-Src was elevated with 
phosphorylation of Y416 residue, it is uncertain that activation of c-Cbl was 
requisitely involved in this process. The precise mechanism underlying
interaction between c-Src and c-Cbl remains to be elucidated.
Neddylation controls stability and activity of c-Src, most likely affecting 
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the downstream molecules. Under the inhibition of neddylation by MLN4924, 
not only Y416 of c-Src but also Y845 of EGFR, which is c-Src-dependent 
phosphorylated residue, was phosphorylated. Also the target kinases of c-Src 
and EGFR such as ERK and Akt, proteins that regulate proliferation and 
migration, were activated through the blockade of neddylation (Zhou et al., 
2016). My results proposed that the inhibition of c-Src neddylation induces
activation of PI3K/Akt/mTOR pathway, which results in promotion of cell 
migration in lung cancer cell line, H1299 (Fig 10). A selective Src inhibitor,
PP2, interrupts activation of Akt and mTOR, suggesting c-Src is an upstream 
kinase of these molecules. Furthermore, inhibitors of this pathway effectively 
blocked cell migration induced by MLN4924. It was reported that c-Src 
mediates cell motility through diverse pathways including PI3K/Akt, 
Ras/ERK/MAPK, and plenty of other adhesion proteins (Kumar et al., 2003; 
Guarino, 2004; Zhang et al., 2012; Wu et al., 2016). Among these, Akt 
mediates cell migration through activation of various transcription factors 
such as HIF-1a, SNAI1, TWIST (Xue et al., 2012; Filippi et al, 2014; Yang et 
al., 2016). The accurate mechanisms underlying regulation of cell migration 
mediated by c-Src neddylation ought to be discovered.
To inhibit conjugation of NEDD8, I used MLN4924, a promising anti-
cancer agent. Many studies reported that MLN4924 prevented tumor cell 
proliferation and migration in various cancers (Wang et al., 2014; Kuo et al., 
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2015; Lan et al., 2016, 44, 58). However, latest research detected that the 
physiological outcomes of MLN4924 were reversed in case of low
concentrations. Zhou et al reported that treatment of MLN4924 caused 
striking effects on tumor sphere formation and wound healing of epithelial 
cells (Zhou et al., 2016). Also our laboratory presented that blocking of
neddylation through MLN4924 elevated cell motility via caveolin-1
dependent way (unpublished data). In line with these results, my data showed 
that the inhibition of c-Src neddylation by MLN4924 improved c-Src activity, 
which promotes cell motility (Fig 7). Considering c-Src is one of the main 
upstream kinases in the cell, it is reasonable to suggest that the blockade of c-
Src neddylation can be a crucial mechanism in MLN4924-induced cell 
migration. More research on this novel medicine is crucial and necessary. 
In conclusion, Neddylation of c-Src mediated by c-Cbl promotes further 
ubiquitination of itself. Also the blockade of neddylation elevates tumor 
migration through PI3K/Akt/mTOR pathway in a c-Src-dependent manner. 
These consequences can provide better understanding for the role of c-Src 
modification and NEDD8 process in cancer physiology.
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국 문 초 록
c-Src은 최초로 발견된 종양 유전자로서 세포의 증식, 부착, 이동성, 
혈관 신생 등의 종양 진행을 조절하는 인자이다. Tyrosine 416이 인산
화된 c-Src의 안정성은 유비퀴틴화에 의해 조절된다는 것이 잘 알려
져 있으나, 다른 번역 이후의 구조변환에 의한 조절은 밝혀지지 않
았다. 
본 연구에서는 c-Src의 안정성이 네딜화에 의해 조절된다는 것을 처
음으로 밝혔다. 더욱이, c-Cbl에 의해 c-Src의 네딜화가 매개됨을 밝
힘으로써 c-Cbl이 E3 ligase로서 작용하는 것을 밝혔다. 네딜화 억제
제인 MLN4924 또는 si-NEDD8 또는 네딜화 E1효소인 APPBP1의
siRNA로 발현을 억제시킴으로써 네딜화를 차단시켰을 때, c-Src의 안
정성이 증가하였으며 그 결과 암 세포의 이동이 증가하였다. 네딜화
억제로 유도된 위 현상들은 PP2로 c-Src의 활성을 억제하거나, c-Src
의 siRNA를 처리하여 c-Src의 발현을 억제하였을 때, 네딜화 억제에
의해 증가되었던 세포이동이 다시 감소하였다. 또한 네딜화 억제는
c-Src 의존적으로 Akt/mTOR 신호전달 과정을 활성화시켰으며, 이 신
호전달 경로 억제제들과 네딜화 억제제인 MLN4924의 동시 투약은
MLN4924에 의해 증가되었던 세포 이동을 다시 억제하였다. 
연구 결과를 종합해 볼 때, c-Src이 c-Cbl에 의해 네딜화되는 새로운
표적 기질이며, c-Src의 네딜화은 단백질의 유비퀴틴화를 유도하여 c-
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Src을 단백질 수준에서 파괴를 촉진하는 현상임을 밝혔다. 또한 c-
Src의 네딜화에 의해 유도된 단백질의 불안정성은 결과적으로
Akt/mTOR 신호전달 경로를 억제하게 되어 암 세포의 이동을 감소
시킨다는 것을 발견하였다. 본 연구결과를 통해 종양의 진행과정에
서 c-Src의 네딜화는 암세포의 이동을 억제하여 전이를 막는 새로운
조절기전이 될 가능성을 제시하였다.
주요어: c-Src, c-Cbl, neddylation, ubiquitination, PI3K/Akt/mTOR, 세포
이동
학번: 2014-25067
